Literature DB >> 11204595

Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ.

H Sandberg1, A Almstedt, J Brandt, E Gray, L Holmquist, U Oswaldsson, S Sebring, M Mikaelsson.   

Abstract

Recombinant factor VIII SQ (r-VIII SQ), ReFacto, is a recombinant factor VIII product similar to the smallest active factor VIII protein found in plasma-derived factor VIII (p-VIII) concentrates. The protein comprises two polypeptide chains of 80 and 90 kDa and lacks the major part of the heavily glycosylated B-domain i.e. amino acids Gln744 to Ser1637. r-VIII SQ retains six potential glycosylation sites for N-linked oligosaccharides at asparagine residues 41, 239, 582, 1685, 1810 and 2118. We describe a thorough comparison of the characteristics of r-VIII SQ with those of p-VIII. The primary and secondary structures of r-VIII SQ were in good agreement with that of B-domain-deleted p-VIII (p-VIII-LMW) as shown by SDS-PAGE, Western blotting with antifactor VIII antibodies, tryptic mapping, amino acid sequence analysis and circular dichroism spectroscopy. A few divergences also existed. Thus r-VIII SQ was shown to contain a small amount of the single chain primary translation product of 170 kDa and also the product specific sequence of 14 amino acids, the SQ-link, in the C-terminal end of the 90 kDa chain. It was shown that r-VIII SQ had a high specific activity of about 14,000 IU VIII:C/mg as determined by use of a chromogenic substrate assay. The r-VIII SQ protein was comparable to p-VIII forms with a retained B-domain, in terms of potency measured by a chromogenic substrate or a two-stage clotting assay, in interactions with thrombin, and with activated protein C (APC) in combination with Protein S. The ability of r-VIII SQ to participate as a cofactor in factor Xa generation in a mixture of factors IXa and X, phospholipid and calcium was in conformity with that of p-VIII. Furthermore r-VIII SQ had a good binding capacity for phospholipid vesicles and von Willebrand factor (vWF) as shown in gel filtration studies. The same kinetics in binding to von Willebrand factor was found for r-VIII SQ and p-VIII as determined by real-time biospecific interaction analysis (BIA) with use of the BIAcore instrument. The apparent association rate constant was 4 x 10(6) M(-1)s(-1). Two dissociation rate constants were found, 1 X 10(-2)s(-1) and 4 x 10(-4)s(-1). The results extend the present knowledge that the factor VIII B-domain is dispensable for the factor VIII cofactor function in hemostasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11204595

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

1.  Circumventing furin enhances factor VIII biological activity and ameliorates bleeding phenotypes in hemophilia models.

Authors:  Joshua I Siner; Benjamin J Samelson-Jones; Julie M Crudele; Robert A French; Benjamin J Lee; Shanzhen Zhou; Elizabeth Merricks; Robin Raymer; Timothy C Nichols; Rodney M Camire; Valder R Arruda
Journal:  JCI Insight       Date:  2016-10-06

2.  Product-dependent anti-factor VIII antibodies.

Authors:  S Butenas; J Krudysz-Amblo; G E Rivard; K G Mann
Journal:  Haemophilia       Date:  2013-04-04       Impact factor: 4.287

Review 3.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

Review 4.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.

Authors:  Jenny McIntosh; Peter J Lenting; Cecilia Rosales; Doyoung Lee; Samira Rabbanian; Deepak Raj; Nishil Patel; Edward G D Tuddenham; Olivier D Christophe; John H McVey; Simon Waddington; Arthur W Nienhuis; John T Gray; Paolo Fagone; Federico Mingozzi; Shang-Zhen Zhou; Katherine A High; Maria Cancio; Catherine Y C Ng; Junfang Zhou; Christopher L Morton; Andrew M Davidoff; Amit C Nathwani
Journal:  Blood       Date:  2013-02-20       Impact factor: 22.113

6.  Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study.

Authors:  Divi Venkateswarlu
Journal:  BMC Struct Biol       Date:  2010-02-25

7.  Potency and mass of factor VIII in FVIII products.

Authors:  S Butenas; B Parhami-Seren; M T Gissel; E D Gomperts; D N Fass; K G Mann
Journal:  Haemophilia       Date:  2008-08-06       Impact factor: 4.287

Review 8.  A new recombinant factor VIII: from genetics to clinical use.

Authors:  Elena Santagostino
Journal:  Drug Des Devel Ther       Date:  2014-12-12       Impact factor: 4.162

9.  Blood Clotting Factor VIII: From Evolution to Therapy.

Authors:  N A Orlova; S V Kovnir; I I Vorobiev; A G Gabibov; A I Vorobiev
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

10.  Transgene-host cell interactions mediate significant influences on the production, stability, and function of recombinant canine FVIII.

Authors:  Bredon Crawford; Margareth C Ozelo; Kenichi Ogiwara; James Ahlin; Silvia Albanez; Carol Hegadorn; Lori Harpell; Christine Hough; David Lillicrap
Journal:  Mol Ther Methods Clin Dev       Date:  2015-11-18       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.